Psychemedics Corporation

Psychemedics pioneered the use of hair drug testing, and remains by far the largest and leading supplier of drugs of abuse hair testing worldwide. Psychemedics is the only company to develop and patent a process that releases virtually 100% of the drugs from the inside of the hair, providing the greatest ability to detect drug use. Offering over 25 years of global experience, Psychemedics has provided its expertise and superior drug testing technology to thousands of organizations to aid in transitioning their drug screening programs to achieve the goal of a drug-free environment. Our drug testing services are trusted by over 10% of the Fortune 500 companies, numerous international organizations, many of the largest police departments, rehabilitation programs, schools and parents throughout the world. Psychemedics established its scientific and market leadership position through dedicated research and development efforts. Psychemedics has set the industry standards for sensitivity, robustness, quality and consistency. A partnership with Psychemedics ensures that your drug testing program stays current as drug challenges change and evolve.
Company Growth (employees)
Type
Public
HQ
Acton, US
Founded
1985
Size (employees)
206 (est)
Psychemedics Corporation was founded in 1985 and is headquartered in Acton, US

Psychemedics Corporation Office Locations

Psychemedics Corporation has an office in Acton
Acton, US (HQ)
200 125 Nagog Park

Psychemedics Corporation Financials and Metrics

Psychemedics Corporation Financials

Psychemedics Corporation's revenue was reported to be $10.2 m in Q1, 2017
USD

Revenue (Q1, 2017)

10.2 m

Gross profit (Q1, 2017)

5.3 m

Gross profit margin (Q1, 2017), %

52%

EBIT (Q1, 2017)

2.3 m

Market capitalization (17-Oct-2017)

93.3 m

Cash (31-Dec-2016)

3.9 m

EV

92.7 m
Psychemedics Corporation's current market capitalization is $93.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

26.9 m29.2 m27 m39 m

Revenue growth, %

9%(8%)45%

EBIT

5.7 m4.7 m1.5 m10.1 m

EBIT margin, %

21%16%5%26%
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

6.7 m9.7 m11.8 m10.2 m

Cost of goods sold

3.9 m4.5 m4.7 m4.9 m

Gross profit

2.7 m5.2 m7.1 m5.3 m

Gross profit Margin, %

41%54%60%52%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

4 m3.6 m2.7 m3.9 m

Accounts Receivable

4.4 m4.1 m3.5 m5.8 m

Inventories

769.3 k690 k1.1 m1.1 m

Current Assets

10 m10.6 m8.5 m10.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

3.8 m3.2 m1.5 m6.7 m

Depreciation and Amortization

872.2 k1.1 m1.7 m2.3 m

Accounts Receivable

251.9 k290.7 k539.4 k(2.3 m)

Accounts Payable

(159.2 k)334.5 k(97.8 k)144 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

1.6 m2.7 m

Accounts Payable

1.2 m683.2 k475 k589.6 k635.4 k1.3 m988.5 k1.1 m622 k
USDY, 2017

EV/EBIT

40.9 x

Revenue/Employee

49.6 k
Show all financial metrics

Psychemedics Corporation Market Value History

Traffic Overview of Psychemedics Corporation

Psychemedics Corporation Online and Social Media Presence

Psychemedics Corporation Company Life and Culture

You may also be interested in